USFDA inspection: Natco Pharma gets 8 observations for Hyderabad Pharma Division
Advertisement
Hyderabad: Natco Pharma Limited has received eight observations from the United States Food and Drug Administration (USFDA) at the end of the inspection at the company's Pharma Division located in Kothur Hyderabad, India.
The inspection was conducted from 9th October, 2023 to 18th October, 2023.
"The company is confident of addressing all the observations within the stipulated time and working with USFDA to close them at the earliest," Natco stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.